Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study.
Neurourol Urodyn
; 27(6): 540-7, 2008.
Article
em En
| MEDLINE
| ID: mdl-18663723
ABSTRACT
BACKGROUND AND AIMS:
Overactive bladder (OAB), a chronic condition requiring long-term management, is associated with substantial impact on health-related quality of life (HRQoL). The short-term benefits of antimuscarinic drug treatment are well known. Here we investigate the impact on HRQoL of long-term treatment with the M(3)-selective muscarinic receptor antagonist darifenacin over 2 years.METHODS:
HRQoL was assessed using the King's Health Questionnaire (KHQ) for patients with 'wet' OAB treated with darifenacin (7.5/15 mg once daily [o.d.]) in an open-label 2-year extension of two double-blind feeder studies. Data were also analyzed for the subset of patients who continued darifenacin 7.5/15 mg o.d. directly into the extension study from the feeder studies (the 'darifenacin continuation' group), and also older patients (>or=65 years) and men within this group.RESULTS:
The total study population comprised 716 patients, of whom 303 patients formed the 'darifenacin continuation' group (including 85 patients >or=65 years and 41 men). Substantial impairment of HRQoL was noted in baseline KHQ assessments. KHQ scores improved significantly from feeder-study baseline to extension study end/last visit in eight of the nine domains, with more than 50% of patients reporting improvements in seven of the nine domains. Despite fewer patients, significant improvements in KHQ scores were also observed in the subsets of older patients (>or=65 years) and men. Almost two-thirds of the 'darifenacin continuation' group were either satisfied or extremely satisfied with treatment.CONCLUSIONS:
Long-term darifenacin treatment was associated with significant and clinically meaningful improvements in HRQoL for patients with 'wet' OAB over 2 years.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Pirrolidinas
/
Qualidade de Vida
/
Benzofuranos
/
Antagonistas Muscarínicos
/
Receptor Muscarínico M3
/
Bexiga Urinária Hiperativa
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
America do norte
/
Europa
/
Oceania
Idioma:
En
Revista:
Neurourol Urodyn
Ano de publicação:
2008
Tipo de documento:
Article
País de afiliação:
Austrália